CALGB/SWOG 80702 was supported by grants (U10CA180821, U10CA180835, U10CA180882, and U10CA180888) from the National Cancer Institute; IDEA France by Institut National du Cancer and a grant (PHRC2009) from Programme Hospitalier de Recherche Clinique en Cancérologie; SCOT by a grant (EME 09/800/34) from the National Institute for Health Research, Efficacy and Mechanism Evaluation, the National Institute for Health Research, Health Technology Assessment, and a grant (C1348/A15960) from Cancer Research United Kingdom; ACHIEVE by the Japanese Foundation for Multidisciplinary Cancer Treatment; TOSCA by a grant (FARM 5RWTWZ) from L’Agenzia Italiana del Farmaco; and HORG by the HORG Foundation.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
Dr. Grothey reports receiving grant support and honoraria, paid to the Mayo Clinic, from Genentech/Roche, Boston Biomedical, Bayer, Amgen, Merck/MSD, and Boehringer Ingelheim and grant support, paid to the Mayo Clinic, from Eisai; Dr. Yoshino, receiving grant support from GlaxoSmithKline and Boehringer Ingelheim; Dr. Taieb, receiving lecture fees, advisory board fees, and reimbursement for attending meetings from Amgen, Roche, Merck, and Servier and lecture fees and advisory board fees from Baxalta, Eli Lilly, Sanofi, Celgene, and Sirtex; Dr. Souglakos, receiving grant support, consulting fees, lecture fees, and advisory board fees, paid to his institution, from Amgen, Roche, and Merck, grant support, consulting fees, and lecture fees from Sanofi, consulting fees from Servier, and lecture fees from Merck/MSD; Dr. Shi, receiving consulting fees and honoraria from Bayer HealthCare Pharmaceuticals; Dr. Labianca, receiving consulting fees from Roche, Sanofi Aventis, and Merck Serono; Dr. Meyerhardt, receiving consulting fees and advisory board fees from Genentech and honoraria from Chugai; Dr. Vernerey, receiving advisory board fees from HalioDx; Dr. Yamanaka, receiving honoraria from Chugai Pharma and Boehringer Ingelheim, grant support and honoraria from Takeda Pharma, and consulting fees from Gilead Sciences; Dr. Renfro, receiving consulting fees from Ignyta and advisory board fees from Bayer; Dr. Saunders, receiving advisory board fees and lecture fees from Roche, Merck, Sanofi, Amgen, and Servier and advisory board fees from Eisai; Dr. Andre, receiving lecture fees and consulting fees from Roche and Sanofi Aventis and lecture fees from Yakult and Baxter; and Dr. Iveson, receiving honoraria from Eli Lilly, advisory board fees and travel support from Servier, advisory board fees from Roche and Celgene, and travel support from Bayer. No other potential conflict of interest relevant to this article was reported.
We acknowledge the contributions of the late Irene Floriani and late Franck Bonnetain to this international collaboration.